JP2022507025A5 - - Google Patents

Info

Publication number
JP2022507025A5
JP2022507025A5 JP2021524166A JP2021524166A JP2022507025A5 JP 2022507025 A5 JP2022507025 A5 JP 2022507025A5 JP 2021524166 A JP2021524166 A JP 2021524166A JP 2021524166 A JP2021524166 A JP 2021524166A JP 2022507025 A5 JP2022507025 A5 JP 2022507025A5
Authority
JP
Japan
Prior art keywords
cancer
composition according
represents hydrogen
phenyl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021524166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507025A (ja
JP7623279B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059602 external-priority patent/WO2020095256A1/en
Publication of JP2022507025A publication Critical patent/JP2022507025A/ja
Publication of JP2022507025A5 publication Critical patent/JP2022507025A5/ja
Priority to JP2025006295A priority Critical patent/JP2025063207A/ja
Application granted granted Critical
Publication of JP7623279B2 publication Critical patent/JP7623279B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021524166A 2018-11-08 2019-11-08 小分子cd-47阻害剤の他の抗癌剤との組み合わせ Active JP7623279B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025006295A JP2025063207A (ja) 2018-11-08 2025-01-16 小分子cd-47阻害剤の他の抗癌剤との組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201841042108 2018-11-08
IN201841042108 2018-11-08
PCT/IB2019/059602 WO2020095256A1 (en) 2018-11-08 2019-11-08 Combination of small molecule cd-47 inhibitors with other anti-cancer agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025006295A Division JP2025063207A (ja) 2018-11-08 2025-01-16 小分子cd-47阻害剤の他の抗癌剤との組み合わせ

Publications (3)

Publication Number Publication Date
JP2022507025A JP2022507025A (ja) 2022-01-18
JP2022507025A5 true JP2022507025A5 (cg-RX-API-DMAC7.html) 2022-11-11
JP7623279B2 JP7623279B2 (ja) 2025-01-28

Family

ID=69159806

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524166A Active JP7623279B2 (ja) 2018-11-08 2019-11-08 小分子cd-47阻害剤の他の抗癌剤との組み合わせ
JP2025006295A Pending JP2025063207A (ja) 2018-11-08 2025-01-16 小分子cd-47阻害剤の他の抗癌剤との組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025006295A Pending JP2025063207A (ja) 2018-11-08 2025-01-16 小分子cd-47阻害剤の他の抗癌剤との組み合わせ

Country Status (14)

Country Link
US (3) US11311517B2 (cg-RX-API-DMAC7.html)
EP (1) EP3876931A1 (cg-RX-API-DMAC7.html)
JP (2) JP7623279B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210088584A (cg-RX-API-DMAC7.html)
CN (2) CN120305258A (cg-RX-API-DMAC7.html)
AU (1) AU2019375193A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008781A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118843A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190776A1 (cg-RX-API-DMAC7.html)
IL (1) IL282972B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021005240A (cg-RX-API-DMAC7.html)
PH (1) PH12021550832A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202104192TA (cg-RX-API-DMAC7.html)
WO (1) WO2020095256A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020014202A2 (pt) * 2018-01-12 2020-12-01 Aurigene Discovery Technologies Limited compostos de 1,2,4-oxadiazol como inibidores de vias de sinalização cd47
CN116887864A (zh) * 2021-02-10 2023-10-13 华上生技医药股份有限公司 一种用于克服免疫抑制或刺激抗癌免疫应答的药物组合和方法
CN113018415B (zh) * 2021-03-17 2022-07-01 遵义医科大学 一种药物组合及其应用
CN113750215B (zh) * 2021-09-24 2023-06-23 暨南大学 用于治疗肿瘤的联合药物
CN122029162A (zh) 2023-10-19 2026-05-12 奥瑞基尼肿瘤有限公司 CD47-SIRPα通路抑制剂的药学上可接受的盐
WO2025229629A1 (en) 2024-05-03 2025-11-06 Aurigene Oncology Limited Combination therapy using a cd47-sirp-alpha blocking agent and azacitidine
WO2025229631A2 (en) * 2024-05-03 2025-11-06 Aurigene Oncology Limited A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER
CN118453879B (zh) * 2024-05-23 2025-10-03 大连医科大学附属第二医院 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2104501B1 (en) * 2006-12-13 2014-03-12 Merck Sharp & Dohme Corp. Methods of cancer treatment with igf1r inhibitors
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
KR102894264B1 (ko) * 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
EA201791621A1 (ru) 2015-03-10 2018-02-28 Ауриджен Дискавери Текнолоджис Лимитед 3-замещенные-1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
WO2016168246A1 (en) 2015-04-14 2016-10-20 The Procter & Gamble Company Solid conditioning composition
CN104804093A (zh) 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
US9650441B2 (en) 2015-09-21 2017-05-16 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
WO2017194627A1 (en) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) New compounds and pharmaceutical use thereof in the treatment of cancer
EP3243522A1 (en) 2016-05-10 2017-11-15 Université Pierre et Marie Curie (Paris 6) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
BR112019007872A2 (pt) * 2016-10-20 2019-07-02 Aurigene Discovery Technologies Limited inibidores duplos de vista e das vias pd-1
BR112020014202A2 (pt) * 2018-01-12 2020-12-01 Aurigene Discovery Technologies Limited compostos de 1,2,4-oxadiazol como inibidores de vias de sinalização cd47
EP3768259A4 (en) * 2018-03-14 2022-04-06 Aurigene Discovery Technologies Limited METHODS OF MODULATION OF TIGIT AND PD-1 SIGNALING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS

Similar Documents

Publication Publication Date Title
JP2024531477A5 (cg-RX-API-DMAC7.html)
ES2808988T3 (es) Composiciones y métodos para inhibir la actividad arginasa
JP6514647B2 (ja) 薬物組み合わせ
RU2018130330A (ru) Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией
JP2022141916A5 (cg-RX-API-DMAC7.html)
JP7623279B2 (ja) 小分子cd-47阻害剤の他の抗癌剤との組み合わせ
UA126421C2 (uk) Інгібітори pd-1/pd-l1
TW201740943A (zh) Hdac抑制劑與pd-1抑制劑之組合治療
JP7491220B2 (ja) 免疫チェックポイント阻害薬およびfolfirinox療法との併用によるがん治療
KR20200103040A (ko) Tlr7 아고니스트를 포함하는 병용 약물
JP2023549540A5 (cg-RX-API-DMAC7.html)
JP2022537358A5 (cg-RX-API-DMAC7.html)
JP2021113206A (ja) 2−(4−クロロフェニル)−n−((2−(2,6−ジオキソピペリジン−3−イル)−1−オキソイソインドリン−5−イル)メチル)−2,2−ジフルオロアセトアミドの製剤
JP7417804B2 (ja) 1,2,4-オキサジアゾール化合物を用いてtigitおよびpd-1のシグナル伝達経路をモジュレートする方法
JP2021528496A5 (cg-RX-API-DMAC7.html)
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
TW202340142A (zh) Gcl抑制劑
RU2025105118A (ru) Комбинированная терапия ингибиторами cdk7 с другими противораковыми агентами
RU2025135585A (ru) Кристаллическая форма ингибитора enpp1
WO2024229440A2 (en) Methods of treating cancer using mdm2 inhibitors and compositions related thereto
EA045738B1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами